Author:
Battalapalli Dheerendranath,Chakraborty Purbali,Jain Disha,Obaro Stephen K.,Gurkan Umut,Bonomo Robert A.,Draz Mohamed
Abstract
AbstractRapid and reliable point-of-care (POC) diagnostic tests can make a significant impact on global health. One of the most common approaches for developing POC systems is the use of target-specific biomolecules. However, the conjugation of biomolecules can result in decreased activity, which may compromise the analytical performance and accuracy of the developed systems. Here, we present a polymer-based cross-linking protocol for controlled and directed conjugation of biological molecules. Our protocol utilizes a bifunctional thiol-polyethylene glycol (PEG)-hydrazide polymer to enable site-directed conjugation of IgG antibodies to the surface of screen-printed metal electrodes. The metal surface of the electrodes is first modified with thiolated PEG molecules, leaving the hydrazide groups available to react with the aldehyde group in Fc fragments of the oxidized IgG antibodies. UsingKlebsiella pneumoniaecarbapenemase-2 (KPC2) antibody as a model antibody used for antimicrobial resistance (AMR) testing, our results demonstrate a ∼10-fold increase in antibody coupling, compared with the standardN-hydroxysuccinimide (NHS)-based conjugation chemistry, and effective capture (> 94%) of the target KPC2 enzyme antigen on the surface of modified electrodes. This straightforward and easy-to-perform strategy of site-directed antibody conjugation can be engineered for coupling other protein and non-protein-based biological molecules commonly used in POC testing and development, thus enhancing the potential for improved diagnostic accuracy and performance.
Publisher
Cold Spring Harbor Laboratory
Reference44 articles.
1. Point-of-Care Diagnostics for Global Health
2. Lateral flow (immuno)assay: its strengths, weaknesses, opportunities and threats. A literature survey
3. Enzyme Immunoassay (EIA)/Enzyme-Linked Immunosorbent Assay (ELISA)
4. Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast CancerEngineered Trastuzumab-DM1 THIOMAB Drug Conjugate;Clinical cancer research,2010
5. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates;Chemistry & biology,2013